About Neogenomics laboratories
NeoGenomics Laboratories: Revolutionizing Precision Oncology Testing
NeoGenomics Laboratories is a leading provider of cancer-focused genetic testing services that empower healthcare professionals to optimize patient care. The company was founded in 2001 and has since grown to become one of the most trusted names in precision oncology testing, with a reputation for delivering accurate, reliable results that help guide treatment decisions.
At NeoGenomics, the focus is on providing comprehensive genomic profiling solutions that enable physicians to identify the specific genetic mutations driving a patient's cancer. By analyzing tumor tissue samples using advanced molecular diagnostic techniques, NeoGenomics can provide clinicians with valuable insights into the underlying biology of each patient's cancer. This information can then be used to develop personalized treatment plans tailored to each individual's unique needs.
One of the key strengths of NeoGenomics is its commitment to innovation and technology. The company has invested heavily in developing cutting-edge genomic sequencing platforms and bioinformatics tools that enable it to deliver highly accurate and clinically relevant test results quickly and efficiently. This focus on innovation has helped NeoGenomics stay at the forefront of precision oncology testing, continually pushing the boundaries of what is possible in terms of identifying new biomarkers and developing novel therapeutic approaches.
Another important aspect of NeoGenomics' approach is its dedication to collaboration and partnership. The company works closely with healthcare providers across all stages of cancer care, from diagnosis through treatment planning and monitoring. By building strong relationships with physicians, researchers, pharmaceutical companies, and other stakeholders in the oncology community, NeoGenomics is able to stay abreast of emerging trends and developments in precision medicine while also contributing its own expertise towards advancing our understanding of cancer biology.
In terms of specific services offered by NeoGenomics Laboratories, there are several key areas where the company excels:
Comprehensive Genomic Profiling (CGP): CGP involves analyzing tumor tissue samples for hundreds or even thousands of genetic mutations simultaneously using next-generation sequencing (NGS) technology. This approach provides a more complete picture than traditional single-gene tests or targeted panels because it allows clinicians to identify multiple potential targets for therapy based on an individual patient's unique genomic profile.
Liquid Biopsy: Liquid biopsy involves analyzing circulating tumor DNA (ctDNA) or other biomarkers found in blood or other bodily fluids as a non-invasive way to monitor disease progression or response to therapy over time.
FISH Testing: Fluorescence In Situ Hybridization (FISH) testing uses fluorescent probes attached directly onto chromosomes within cells under examination which helps detect chromosomal abnormalities such as translocations which are common among many types cancers including leukemia’s lymphomas etc.,
Immunohistochemistry (IHC): IHC involves staining tissue samples with antibodies against specific proteins expressed by tumors cells which helps determine whether certain proteins are present at higher levels than normal tissues indicating potential targets for therapy.
Overall Neogenomic laboratories have been instrumental when it comes down providing precise diagnosis through their innovative technologies like Comprehensive Genomic Profiling(CGPs), Liquid Biopsy,FISH Testing & Immunohistochemistry(IHC). They have been working closely with healthcare providers across all stages from diagnosis through treatment planning & monitoring making them one-stop-shop for all your Oncological needs!
neogenomics.com
